A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 31, 2004

Study Completion Date

July 31, 2005

Conditions
Renal Cell CarcinomaMetastases
Interventions
DRUG

Avastin (bevacizumab)

DRUG

Tarceva (erlotinib HCl)

Trial Locations (20)

10016

NYU School of Medicine, New York

10466

Our Lady of Mercy Medical Center, The Bronx

11030

North Shore University Hospital, Manhasset

19004

University of Pennsylvania, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

27609

Raleigh Hematology Oncology, Raleigh

28601

Northwestern Carolina Oncology & Hematology, Hickory

33428

Lynn Regional Cancer Center - West, Boca Raton

44195

The Cleveland Clinic, Cleveland

48201

Wayne State University / Harper University Hospital, Detroit

64507

St. Joseph Oncology, Saint Joseph

70121

Ochsner Cancer Institute, New Orleans

80010

UCHSC - Urologic Oncology, Aurora

90095

UCLA School of Medicine, Los Angeles

92120

Kaiser Permanente Medical Group, San Diego

94305

Stanford University Medical Center, Stanford

94520

Bay Area Cancer Research Group, Concord

06902

Bennett Cancer Center, Stamford

02215

Beth Israel Deaconess Medical Center, Boston

07601

The Cancer Center at Hackensack University Medical Center, Hackensack

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT00081614 - A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter